Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|February 1, 2022
Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthmaBob Geng, Anne E Dixon, Jinnie Ko, et al.
The British Journal of Dermatology|June 5, 2024
The role of OX40 ligand/OX40 axis signalling in atopic dermatitisEmma Guttman-Yassky, Michael Croft, Bob Geng, et al.
American Journal of Hematology|January 23, 2010
Bone marrow biopsy in patients with hepatitis C virus infection: spectrum of findings and diagnostic utilityJeffery M Klco, Bob Geng, Elizabeth M Brunt, et al.
The American Journal of Dermatopathology|November 20, 2013
Cutaneous granulomas and epidermodysplasia verruciformis in early onset combined immunodeficiency syndromeYen T Wang, Bob Geng, Ki-Young Yoo, et al.
Haematologica|July 17, 2025
Comparative single-cell lineage bias in human and murine hematopoietic stem cellsIsaac Shamie, Meghan Bliss-Moreau, Jamie Casey Lee, et al.
Immunotherapy|May 6, 2021
Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig® [octanorm])Roger H Kobayashi, Jose Fernando Mandujano, Syed M Rehman, et al.
Frontiers in Immunology|February 20, 2019
Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary ImmunodeficienciesRoger H Kobayashi, Sudhir Gupta, Isaac Melamed, et al.
Allergy and Asthma Proceedings|April 29, 2026
Clinical characteristics, type 2 comorbidities, and treatment responses in pediatric and adult chronic spontaneous urticaria: A multicenter retrospective cohort studyKathryn Smiley, Lauren Galli, Amanda Grippen Goddard, et al.
Frontiers in Immunology|January 6, 2023
Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficienciesRoger H Kobayashi, Sudhir Gupta, Isaac Melamed, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 13, 2025
Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by AgeMichael J Cork, Mette Deleuran, Bob Geng, et al.
Pageof 6